Core Points - The document outlines the procedures and regulations for the resignation of directors and senior management at Yingke Medical Technology Co., Ltd, aiming to maintain corporate governance stability and protect the rights of the company and its shareholders [1][2]. Chapter Summaries Chapter 1: General Provisions - The regulations are established based on relevant laws and the company's articles of association to standardize the resignation process of directors and senior management [1]. Chapter 2: Resignation Circumstances and Procedures - Directors can resign before their term ends by submitting a written resignation report, which becomes effective upon receipt by the company, and the company must disclose this within two trading days [2]. - If a director resigns and it results in the board falling below the legal minimum number of members, the director must continue to fulfill their duties until a new director is appointed [2]. - The company must complete the election of a new director within sixty days after a resignation to ensure compliance with legal and regulatory requirements [2]. - Senior management can also resign before their term ends, with specific procedures outlined in their labor contracts [2]. Chapter 3: Handover Procedures and Obligations - Resigning directors and senior management must complete handover procedures within five working days after their resignation, including transferring company seals and all relevant documents [3]. - If there are outstanding public commitments, the company can require a written fulfillment plan from the resigning personnel [3]. Chapter 4: Management of Shares Held by Resigning Directors and Senior Management - Resigning directors and senior management are prohibited from transferring their shares within six months of resignation [4]. - There are restrictions on the amount of shares that can be sold during their term and after resignation, ensuring compliance with relevant regulations [4]. Chapter 5: Accountability Mechanism - The board will review and determine accountability measures if a resigning director or senior management fails to fulfill commitments or obligations [5]. - Individuals can appeal the board's decisions regarding accountability within fifteen days [5]. Chapter 6: Supplementary Provisions - Any matters not covered by these regulations or conflicting with national laws will be governed by the relevant laws and the company's articles of association [6].

英科医疗科技股份有限公司 章 程 二〇二五年七月 目 录 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）和其他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司（以下 简称"公司"）。 公司由淄博英科医疗制品有限公司以整体变更方式设立，在淄博市市场监督 管理局注册登记并取得《营业执照》，统一社会信用代码：9137030068946500X7。 第三条 公司于 2017 年 6 月 23 日经中国证券监督管理委员会（以下简称 "中国证监会"）核准，首次向社会公众发行人民币普通股 2,430.9827 万股，于 第四条 公司注册名称：英科医疗科技股份有限公司 公司英文名称： INTCO MEDICAL TECHNOLOGY CO.,LTD. 第五条 公司住所：淄博市临淄区齐鲁化学工业园清田路 18 号 邮政编码：255414 第六条 公司注册资本为人民币 64,170.0369 万元。 第七条 公司为永久存续的股份有限公司。 第八条 董事 ...

Core Viewpoint - The company has established a comprehensive information disclosure system to ensure compliance with legal requirements and protect shareholders' rights, emphasizing the importance of timely, accurate, and complete information dissemination [1][2][3]. Group 1: Information Disclosure Principles - Information disclosure is a continuous responsibility of the company, which must adhere to relevant laws and regulations [2]. - The company must treat all shareholders fairly and disclose information that may significantly impact their decisions in a clear and understandable manner [3][4]. - The company is required to disclose information proactively, especially if it could materially affect shareholders and stakeholders [3][4]. Group 2: Reporting Requirements - The company must disclose periodic reports, including annual, semi-annual, and quarterly reports, within specified timeframes [5][6]. - If the company anticipates that its annual performance or financial status will significantly change, it must issue a performance forecast within one month after the fiscal year ends [6][7]. - The company must also disclose any major events or transactions that could impact its stock price or investment decisions promptly [8][9]. Group 3: Major Transactions and Related Party Transactions - Major transactions, such as asset purchases or sales, must be disclosed if they meet certain thresholds, including a 10% impact on total assets or significant revenue contributions [10][11]. - Related party transactions must also be disclosed if they exceed specified monetary thresholds, ensuring transparency in dealings with affiliated entities [12][13]. Group 4: Other Significant Events - The company must disclose any significant events that could materially affect its securities or investment decisions, including major losses, legal issues, or changes in management [14][15]. - The company is required to report any changes in its operational status or significant external factors that could impact its business [15][16]. Group 5: Information Disclosure Management - The board of directors is responsible for overseeing the information disclosure process, with the chairman being the ultimate responsible party [17][18]. - The company must maintain a structured approach to information disclosure, ensuring that all relevant personnel are informed and comply with disclosure obligations [19][20]. - The company must implement internal controls to ensure the accuracy and timeliness of financial reporting and disclosures [21][22].

英科医疗科技股份有限公司 第一章 总 则 第一条 为有效落实英科医疗科技股份有限公司（以下简称"公司"）风险管理和 流程控制，保障公司经营管理的安全，防范和化解各类风险，提高经营效益和效率， 保护投资者合法权益。根据《中华人民共和国公司法》《中华人民共和国证券法》《企 业内部控制基本规范》《深圳证券交易所创业板股票上市规则》(以下简称《创业板上市 规则》)、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等法律法规以及《英科医疗科技股份有限公司章程》（以下简称《公司章程》），制定 本制度。 第二条 本制度所称的内部控制是指公司董事会、高级管理人员及全体员工为实 现下列控制目标而提供合理保证的过程： （一）确保国家有关法律、法规和公司内部规章制度的贯彻执行； （二）提高公司经营效益和效率； （三）保障公司资产的安全、完整； （四）确保公司信息披露的真实、准确、完整、及时和公平。 第三条 公司内部控制制度应当遵循下列原则： （一）全面性原则。内部控制应当贯穿决策、执行和监督全过程，覆盖公司及其 下属企业的各种业务和事项。 （二）重要性原则。内部控制应当在全面控制的基础上，关注重要业务事 ...

General Provisions - The company establishes guidelines to enhance the role of the board secretary and ensure compliance with relevant laws and regulations [1][2] - The board secretary is a senior management position responsible for the company and the board [1][2] - The board secretary must meet qualifications set by the relevant regulations and pass a qualification exam recognized by the Shenzhen Stock Exchange [1][2] Responsibilities - The board secretary is responsible for organizing information disclosure, managing investor relations, and coordinating communication between the company and stakeholders [5][11] - The board secretary must ensure compliance with information disclosure regulations and maintain confidentiality of sensitive information [13][19] - The board secretary is tasked with preparing board and shareholder meetings, maintaining meeting records, and ensuring the quality of documents submitted for review [12][23] Employment and Termination - The company must promptly announce the appointment of the board secretary, including personal details and qualifications [2][9] - The board secretary can be dismissed for failing to fulfill duties, legal violations, or causing significant losses to the company [26][28] - In the event of a vacancy, the board must appoint an interim secretary and complete the hiring of a new secretary within three months [30][31]

英科医疗科技股份有限公司 第一条 为了进一步规范本公司董事会的议事方式和决策程序，促使董事和董事 会有效地履行其职责，提高董事会规范运作和科学决策水平，根据《中华人民共和国 公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市规则》《深圳 证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》《英科医疗 科技股份有限公司章程》（以下简称《公司章程》）等有关规定，特制定本规则，作 为董事会运作的行为准则。 第二条 董事会下设董事会办公室，处理董事会日常事务。 董事会秘书或证券事务代表兼任董事会办公室负责人，保管董事会和董事会办公 室印章。 第三条 董事会会议分为定期会议和临时会议。 董事会每年应当至少召开两次定期会议。 第四条 在发出召开董事会定期会议的通知前，董事会办公室应当充分征求各董 事的意见，初步形成会议提案后交董事长拟定。 董事长在拟定提案前，应当视需要征求经理和其他高级管理人员的意见。 （三）提议会议召开的时间或者时限、地点和方式； 提案内容应当属于《公司章程》规定的董事会职权范围内的事项，与提案有关的 材料应当一并提交。 第五条 有下列情形之一的，董事会应当召开临时会议： （一 ...

英科医疗科技股份有限公司 第一章 总 则 第一条 为了规范英科医疗科技股份有限公司（以下简称"公司"）对外担 保行为，防范对外担保风险，根据《中华人民共和国公司法》（以下简称《公司 法》）《中华人民共和国民法典》《深圳证券交易所创业板股票上市规则》《上 市公司监管指引第8号——上市公司资金往来、对外担保的监管要求》等法律法 规、部门规章、规范性文件以及《英科医疗科技股份有限公司章程》（以下简称 《公司章程》）的有关规定，结合公司的实际情况，制定本制度。 第二条 本制度所称"对外担保"是指公司为他人提供保证、抵押、质押或 其他形式的担保，即公司与债权人约定，当债务人不履行债务时，公司作为保证 人按照约定履行债务或承担责任。 第三条 本制度所称"对外担保"包括公司对控股子公司的担保。 公司及其控股子公司的对外担保总额，是指包括公司对控股子公司担保在内 的公司对外担保总额与控股子公司对外担保总额之和。 第四条 公司对外担保必须经董事会或者股东会审议，审议后需及时对外披 露。 第五条 公司对外担保应当遵循合法、审慎、互利、安全的原则，严格控制 担保风险。公司有权拒绝任何强令其为他人提供担保的行为。 第六条 公司对外担 ...

General Principles - The company establishes guidelines for external investment control to mitigate risks and enhance investment efficiency based on relevant laws and regulations [1] - External investment includes monetary contributions or contributions of assets such as equity, technology, and real estate [1] Investment Approval Authority - External investments must comply with national regulations and the company's development strategy, aiming for reasonable returns [2] - The board of directors and shareholders' meeting are the primary decision-making bodies for external investments, with specific thresholds for board and shareholder approval [2][3] Pre-Investment Work and Management - The company must conduct feasibility studies for long-term equity investments, including economic indicators and risk assessments [4][5] - Financial asset investments require a proposal detailing investment amounts, types, and expected returns [5] Execution Control of Investments - After approval, the investment plan must specify funding details and responsible personnel, with any changes requiring further approval [6][15] - The company must track the financial health of invested entities and report any anomalies to the board [6][16] Disposal Control of Investments - The procedures for recovering or transferring investments mirror those for initial approvals, with specific conditions outlined for both actions [7][20][21] Supervision and Inspection - The internal audit department is responsible for overseeing external investment activities and ensuring compliance with internal controls [8][24] Responsibilities of Directors and Management - Company directors and management must exercise caution in investment decisions, with accountability for significant losses due to negligence [8][27][28] Miscellaneous - The guidelines will take effect upon approval by the shareholders' meeting and can be revised by the board as necessary [9][30]

Core Viewpoint - The company aims to enhance communication with investors and protect their rights through a structured investor relations management system, ensuring transparency and compliance with relevant laws and regulations [1][2][3]. Group 1: Objectives and Principles of Investor Relations Management - The purpose of investor relations management includes establishing effective communication channels, building a stable investor base, fostering a culture of respect for investors, maximizing overall company benefits, and increasing information disclosure transparency [7][8]. - The basic principles of investor relations management emphasize full disclosure of information, compliance with legal regulations, equal treatment of all investors, honesty and integrity, efficiency in communication, and interactive engagement with investors [8][9]. Group 2: Communication Content and Methods - Key communication topics with investors include the company's development strategy, legal disclosures, operational and financial information, significant events, and corporate culture [10][11]. - Various communication methods are employed, such as regular reports, performance briefings, shareholder meetings, company websites, and interactive platforms, ensuring accessibility and efficiency for investors [11][12]. Group 3: Management Structure and Responsibilities - The board secretary is responsible for investor relations management, supported by the capital securities department, which organizes and coordinates investor relations activities [26][27]. - Responsibilities of investor relations management include analyzing investor demographics, facilitating communication, maintaining public relations, and managing media interactions [29][30]. Group 4: Implementation and Compliance - The company must adhere to information disclosure obligations as mandated by regulatory authorities, ensuring timely and accurate reporting of significant information [31][32]. - In voluntary disclosures, the company should follow fairness principles, ensuring all investors have equal access to information [34][35].

英科医疗科技股份有限公司 第一章 总 则 第一条 为规范英科医疗科技股份有限公司（以下简称"公司"）募集资金 管理，提高募集资金使用效率，根据《中华人民共和国公司法》（以下简称《公 司法》）《中华人民共和国证券法》（以下简称《证券法》）《深圳证券交易所 创业板股票上市规则》（以下简称《上市规则》）《深圳证券交易所上市公司自 律监管指引第2号——创业板上市公司规范运作》（以下简称《规范运作指引》） 《上市公司募集资金监管规则》（以下简称《监管规则》）等有关法律法规、规 范性文件等相关法律、法规和规范性文件以及《英科医疗科技股份有限公司公司 章程》（以下简称《公司章程》）的规定，制定本制度。 第二条 本制度所称募集资金是指公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金，但不包括公司实施股权激励计 划募集的资金。 第三条 公司的董事和高级管理人员应当勤勉尽责，督促公司规范使用募集 资金，自觉维护公司募集资金安全，不得参与、协助或纵容公司擅自或变相改变 募集资金用途。 第四条 公司董事会负责健全并确保本制度的有效实施。 募集资金投资项目通过公司的子公司或公司控制的其他公司实施的，公司确 ...